Gempharmatech LLC
San Diego, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 11175 Flintkote Ave b, San Diego, CA 92121, USA
- Website
- gempharmatech.com
- Founded
- 2017
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $88,710 |
| FY2025 | $58,936 |
| FY2024 | $113,208 |
| FY2023 | $188,460 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $89,040 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Ingenious Targeting Laboratory Inc. | Holbrook, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| The Jackson Laboratory | Bar Harbor, ME | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Cyagen Biomodels LLC | Santa Clara, CA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Ozgene PTY LTD | Bentley, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Taconic Biosciences, Inc. | Germantown, NY | 112990 All Other Animal Production |
About the company
Gempharmatech LLC, a foreign-owned biotechnology company based in San Diego, California, develops specialized laboratory mouse models for federal biomedical research agencies as a prime contractor, competing on a full-and-open basis without set-aside designation. The vendor operates under primary NAICS codes 541714 (Research and Development in Biotechnology) and related codes spanning animal production, biological product manufacturing, and testing services, with a recurring PSC profile centered on live animals for research and reference laboratory testing.
Gempharmatech's customer concentration is heavily concentrated within the National Institutes of Health. The top five NIH institutes account for 95% of combined potential value across all recent awards, anchored by the National Center for Advancing Translational Sciences (2 awards, $338 thousand combined potential value), the National Institute on Drug Abuse ($59 thousand), the National Institute of Child Health and Human Development (3 awards, $44 thousand), the National Institute of Allergy and Infectious Diseases (2 awards, $26 thousand), and the National Institute of Dental and Craniofacial Research ($14 thousand). By award count, NICHD and NCATS tie for the top spot among NIH institutes; by dollar value, NCATS dominates. The vendor also holds a single award from the Department of Veterans Affairs Veterans Integrated Service Network 12 ($13 thousand).
Recent capability work demonstrates Gempharmatech's specialization in humanized and knockout mouse models for preclinical drug discovery. Representative contracts include a $249 thousand sole-source purchase order from NCATS (September 2023) for development of humanized NNMT and SULT1A1 mouse models using CRISPR knock-in technology with biochemical inhibitor testing and maximum tolerated dose determination; a $89 thousand sole-source purchase order from NCATS (September 2026) for recovery and production of 50 male humanized NNMT homozygous mice from cryopreserved sperm and efficacy studies in chronic kidney disease models; and a $59 thousand sole-source purchase order from the National Institute on Drug Abuse (September 2025) for safety evaluation of the compound YC1 in humanized SULT1A1 versus standard SULT1A1 mice. Sole-source justifications center on Gempharmatech's exclusive capability to produce and maintain proprietary mouse colonies and cryopreserved genetic resources developed under prior NIH funding.
Activity is sparse and declining. The vendor received four awards in 2022, three in 2023, two in 2024, and one award each in 2025 and 2026, across eleven total prime awards worth $507 thousand in combined potential value. One award (the NCATS NNMT inhibitor evaluation, $89 thousand) completes within the next twenty-four months and faces recompete exposure. Gempharmatech operates exclusively as a prime contractor with no subcontracting footprint in the source data.
Quick answers
Is Gempharmatech LLC registered in SAM.gov?
Yes. Gempharmatech LLC's SAM.gov registration is active through April 23, 2027.
What is Gempharmatech LLC's CAGE code?
Gempharmatech LLC's CAGE code is 98AV0, and its Unique Entity ID (UEI) is H42SCKKGRTU3.
How much has Gempharmatech LLC received in federal contracts?
Federal contracts obligated $58,936 to Gempharmatech LLC in fiscal year 2025 and $449,314 in fiscal years 2023 through 2027.
What is Gempharmatech LLC's most recent federal award?
Gempharmatech LLC's most recent federal contract award is Ncats: service: evaluation of a lead nnmt inhibitor in humanized mouse models of chronic kidney disease: severable (75N98026P01587), from Office of Logisitics and Acquisition Operations (NIH), on September 11, 2026.
On GovTribe
See Gempharmatech LLC's full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors